Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

According to the published results of the phase 3 DESTINY-Breast02 trial, patients with advanced HER2-positive unresectable and/or metastatic breast cancer previously treated with ado-trastuzumab emtansine who received trastuzumab deruxtecan experienced a median PFS of 17.8 months, compared with 6.9 months among those who received physician’s choice of treatment HR, 0.36; 95% CI, 0.28-0.45; P < .0001).